三生国健：安沐奇塔单抗新药上市申请获批，丰富自免商业化管线

Core Viewpoint - The approval of the new drug Anmukita monoclonal antibody injection (trade name: Yisaituo) by the National Medical Products Administration marks a significant advancement for the company in treating moderate to severe plaque psoriasis in adult patients, enhancing its product pipeline and market competitiveness [1] Group 1: Drug Approval and Clinical Results - The company announced that its self-developed anti-IL-17A humanized monoclonal antibody Anmukita has received approval for market launch [1] - In the pivotal Phase III clinical study, all primary efficacy endpoints and key secondary efficacy endpoints were successfully met, particularly showing significant efficacy in achieving complete skin clearance with the PASI100 indicator [1] - The incidence of anti-drug antibodies (ADA) for Anmukita was only 0.7%, indicating good safety and tolerability [1] Group 2: Treatment Flexibility and Market Impact - Anmukita offers flexible dosing options every 4 or 8 weeks, which may reduce the frequency of medication for patients and lower the long-term treatment time costs and psychological burden [1] - The approval of Anmukita will enrich the company's autoimmune commercialization product pipeline and positively impact its operational development [1] - The announcement stated that this approval will not have a significant impact on the company's current financial status and operating results, but it is expected to have a positive effect on future performance [1]